Reteplase

Reteplase
Names
Trade namesRetavase, Retefuse, Rapilysin, Mirel, others
Clinical data
Drug classTissue plasminogen activator[1]
Main usesHeart attacks[1]
Side effectsBleeding, allergic reaction[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
External links
AHFS/Drugs.comMonograph
Legal
License data
Chemical and physical data
FormulaC1736H2671N499O522S22
Molar mass39589.75 g·mol−1

Reteplase, trade names include Retavase, is a thrombolytic medication primarily used to treat heart attacks.[1] It may also be used to treat certain pulmonary embolisms.[1] It is given by injection into a vein.[1]

Common side effects include bleeding.[2] Other side effects may include allergic reactions and cholesterol embolism.[1] Safety in pregnancy is unclear.[3] It is a recombinant protein form of the human tissue plasminogen activator.[1]

Reteplase was approved for medical use in the United States and Europe in 1996.[2][4] In the United States it costs about 3,600 USD per dose as of 2021.[5]

Medical uses

It should be used with 12 hours of the start of a heart attack.[4]

Mechanism of action

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

References

  1. 1 2 3 4 5 6 7 8 "Reteplase Monograph for Professionals". Drugs.com. Archived from the original on 15 August 2019. Retrieved 16 October 2021.
  2. 1 2 "DailyMed - RETAVASE- reteplase kit". dailymed.nlm.nih.gov. Archived from the original on 17 October 2021. Retrieved 16 October 2021.
  3. ↑ "Reteplase Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 16 October 2021.
  4. 1 2 "Rapilysin". Archived from the original on 27 April 2021. Retrieved 16 October 2021.
  5. ↑ "Retavase Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 October 2021.
External sites:
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.